VERAXA Biotech AG (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company presented the findings as it prepares to engage with potential partners at the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data demonstrated that VERAXA’s BiTAC-ADC technology could distinguish between breast cancer cells and healthy cells in laboratory studies, showing dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest a potential for reduced off-tumor toxicity compared to conventional ADCs, which often cause side effects due to non-specific uptake in healthy tissues.
VERAXA’s proprietary BiTAC approach is designed to activate therapeutic effects only within targeted tumor cells, addressing a key limitation of existing antibody-based therapies. The company maintains a diversified oncology pipeline that includes ADCs, T-cell engagers (TCEs), and other antibody-based formats, all built on its BiTAC platform. The BiTAC-ADC and BiTAC-TCE platforms are being offered for strategic collaborations, with the company seeking partners to advance these technologies toward clinical development.
This announcement follows VERAXA’s recent listing on the NASDAQ Capital Market under the ticker VRXA after completing its business combination with Voyager Acquisition Corp. The listing provides the company with access to public capital markets to support its pipeline expansion.
The ability to spare healthy cells while destroying cancer cells is a critical goal in oncology, as it could lead to therapies with fewer side effects and better patient outcomes. VERAXA’s data, though preliminary, positions the BiTAC platform as a potential next-generation approach in the competitive ADC space, which has seen growing interest from major pharmaceutical companies.
For more information on VERAXA Biotech and its latest developments, visit the company’s newsroom at https://nnw.fm/VRXA.
